SCHEMBL1710090

SCHEMBL1710090

COCCOc1ccccc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
ALDH1A1 P00352 3/20 0.53
GLA P06280 1/20 0.53
MAPT P10636 2/20 0.51
KDM4E B2RXH2 2/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
HPGD P15428 2/20 0.50
DRD2 P14416 2/20 0.50
DRD4 P21917 2/20 0.50
NPC1 O15118 1/20 0.50
TSHR P16473 1/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 3/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47
STAT3 P40763 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21169162 0.94 ALDH1A1 (0.50) TDP1L3MBTL1ALDH1A1GLAMAPT
P-Xylene SCHEMBL817546 0.94 DRD2 (0.55) TDP1L3MBTL1ALDH1A1GLAMAPT
SCHEMBL1592876 0.91 TDP1 (0.60) TDP1L3MBTL1ALDH1A1GLAMAPT
SCHEMBL13313250 0.89 ALDH1A1 (0.56) TDP1L3MBTL1ALDH1A1GLAMAPT
SCHEMBL10272925 0.89 CYP2D6 (0.54) TDP1L3MBTL1ALDH1A1GLAMAPT
SCHEMBL2974587 0.86 MAPT (0.56) TDP1L3MBTL1ALDH1A1MAPTKDM4E
SCHEMBL20005687 0.85 L3MBTL1 (0.58) TDP1L3MBTL1MAPTCYP2D6CYP2C19
Isobutane SCHEMBL27839933 0.85 TDP1 (0.54) TDP1L3MBTL1ALDH1A1MAPTKDM4E
SCHEMBL10491992 0.84 ALDH1A1 (0.55) TDP1L3MBTL1ALDH1A1GLAMAPT
SCHEMBL18312558 0.84 ALDH1A1 (0.55) TDP1L3MBTL1ALDH1A1GLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340287-A1 RECORDING METHOD, AND INK COMPOSITION USED IN RECORDING METHOD DNP FINE CHEMICALS CO., LTD. (JP) 2023-10-26 US disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 US disclosed
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 US disclosed
US-20230151023-A1 PYRIDO[2,3-E]OXAZINE DERIVATIVES AS AGRICULTURAL CHEMICALS GLOBACHEM NV (BE) 2023-05-18 US disclosed
US-20220017491-A1 COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-20 US disclosed
WO-2021151919-A1 PYRIDO[2,3-E]OXAZINE DERIVATIVES AS AGRICULTURAL CHEMICALS GLOBACHEM NV (BE) 2021-08-05 WO disclosed
US-20200371435-A1 BLUE CURABLE RESIN COMPOSITION, BLUE COLOR FILTER, AND DISPLAY DEVICE INCLUDING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-11-26 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
CN-102008729-A Composition for external use ROHTO PHARMA 2011-04-13 CN disclosed
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20090234117-A1 Pyrazolopyrimidine Derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
US-20090234117-A1 Pyrazolopyrimidine Derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
US-7468364-B2 Carbapenem compounds DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-23 US disclosed
CN-101184720-A Reaction apparatus for esterification reaction, esterified product, and method for producing same TOAGOSEI CO LTD (JP) 2008-05-21 CN disclosed
EP-1903045-A1 PYRAZOLOPYRIMIDINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2008-03-26 EP disclosed
CN-101102797-A External composition ROHTO PHARMA (JP) 2008-01-09 CN disclosed
EP-0102324-A2 Lipids and surfactants in an aqueous medium CIBA-GEIGY AG (CH) 1984-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT TDP1 4131/4885L3MBTL1 4883/4885ALDH1A1 947/4885
US-20220017491-A1 COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT YAP1, TEAD2, TEAD1 TDP1 1840/4885L3MBTL1 2354/4885ALDH1A1 2937/4885
US-20090234117-A1 Pyrazolopyrimidine Derivative MC2R, CRHR1, AVPR2 TDP1 3304/4885L3MBTL1 4477/4885ALDH1A1 1328/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R TDP1 4753/4885L3MBTL1 4237/4885ALDH1A1 2977/4885
US-20230151023-A1 PYRIDO[2,3-E]OXAZINE DERIVATIVES AS AGRICULTURAL CHEMICALS PNPO, HPD, PDXK TDP1 2588/4885L3MBTL1 3495/4885ALDH1A1 1673/4885
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use CSF1R, CSF3R, MSR1 TDP1 2301/4885L3MBTL1 2519/4885ALDH1A1 1242/4885
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R TDP1 4753/4885L3MBTL1 4237/4885ALDH1A1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.